title: High-dose methotrexate and primary central nervous system lymphoma.
abstract: Primary central nervous system lymphoma (PCNSL) is a rare disease that is managed differently from other primary brain tumors and other types of systemic lymphomas. The use of high-dose methotrexate (HD-MTX) has improved survival rates. This article describes the experience of a patient treated with HD-MTX and outlines the essential aspects of care for the bedside practitioner. An understanding of the diagnostic workup and principles of treatment can minimize complications and maximize patient function as nurses care for the unique physical and emotional needs of this population.
authors.affiliation: Massachusetts General Hospital, Boston, MA, USA. jfahey1@partners.org
authors.forename: Jean B
authors.initials: JB
authors.lastname: Fahey
authors.forename: Carolyn
authors.initials: C
authors.lastname: DiMaggio
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing*; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D015994:Incidence; D017053:Infection Control; D007262:Infusions, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing*; D008279:Magnetic Resonance Imaging; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009730:Nursing Assessment; D010347:Patient Care Planning; D035583:Rare Diseases; D013238:Stereotaxic Techniques; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate